GenSight Biologics Announces Publication of LUMEVOQ® Safety Data over 5-Year Period in renowned Peer-Reviewed American Journal of Ophthalmology

GenSight Biologics Provides Update on LUMEVOQ® Manufacturing and Commercialization Timelines

GenSight Biologics Announces its 2023 Financial Calendar

Rare Disease Day 2023: GenSight Biologics Raises Awareness of Leber Hereditary Optic Neuropathy (LHON)

GenSight Biologics Announces 1 Year Safety data and Efficacy signals from PIONEER Phase I/II Clinical Trial of GS030, an Optogenetic Treatment Candidate for Retinitis Pigmentosa

GenSight Biologics announces the drawdown of the first EUR 8 million tranche under its credit agreement with the European Investment Bank

GenSight Biologics Reports Cash Position as of December 31, 2022, FY 2022 Revenues and Provides Business Update

GenSight Biologics to Present at Upcoming Investor Conferences

GenSight Biologics secures €12 Million financing through a premium convertible notes issuance to an institutional investor and provides business update

GenSight Biologics Announces Publication of Indirect Comparison of LUMEVOQ® Versus Natural History in ND4-LHON Patients in Peer-Reviewed Journal Ophthalmology and Therapy